ETFs WuXi AppTec Co., Ltd.

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 13/02/2026			5-day change	1st Jan Change
101.91 ^CNY	-2.85%		+0.55%	+12.43%

12/02	Nomura Adjusts WuXi AppTec's Price Target to 142.93 Yuan From 120.85 Yuan, Keeps at Buy	MT
12/02	Nomura Adjusts WuXi AppTec's Price Target to HK$157.07 From HK$132.80, Keeps at Buy	MT

ETFs positioned on WuXi AppTec Co., Ltd.

Name	Varia. Jan 1.	Weight	AuM
LEVERAGE SHARES -3X SHORT CHINA ETP SECURITIES - USD	0.00%	0.1%	0 M€
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	+2.44%	0.01%	33,076 M€
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD	+7.00%	0.01%	32 M€
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	+1.60%	0%	864 M€
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	+1.47%	0%	34 M€
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	+1.13%	0%	186 M€
NOMURA NEXT FUNDS EMERGING MARKET EQUITY MSCI-EM (UNHEDGED) ETF - JPY	+9.18%	0%	20 M€
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF ACC - EUR	+1.15%	0%	85 M€
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR	+1.12%	0%	14 M€

WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .

Employees

39,414

Sector

Biotechnology & Medical Research

Calendar

24/03 - Q4 2025 Earnings Release

More about the company